Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Paraproteinemias 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Cardiotoxicity 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 21enfortumab vedotin 13Gemcitabine 12Nivolumab 8Cisplatin 8Carboplatin 8Magnetic Resonance Spectroscopy 6Specimen Handling 5Docetaxel 5toripalimab 4sacituzumab govitecan 4Paclitaxel 4Ipilimumab 4atezolizumab 3Mitomycin 3Fluorouracil 3disitamab vedotin 2cabozantinib 2avelumab 2Radiosurgery 2Platinum 2Injections 2Immunotherapy 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Biopsy 2zanidatamab 1tremelimumab 1tamibarotene 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Transitional Cell × Blood Cell Count × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡